EMEA in 'positive' responses to Neoprobe

November 2008
Medical Device Daily;11/4/2008, Vol. 12 Issue 215, p8
The article reports on the positive responses given by the European Medicines Agency (EMEA) to the scientific advice submission of Neoprobe regarding RIGScan CR in November 2008. An overview of the EMEA approval is presented. It offers information on the Phase III clinical study to be conducted by Neoprobe in patients with diagnosed primary or metastatic/recurrent colorectal cancer. Company president and chief executive officer David Bupp shares his views on the significance of the scientific advice response.


Related Articles

  • Neoprobe Announces Retirement of David Bupp and Appointment of Mark Pykett as President/CEO Effective April 15th.  // Biomedical Market Newsletter;5/21/2011, p939 

    The article announces the retirement of David Bupp as president and chief executive officer and the appointment of Mark Pykett as its replacement at Neprobe Corp.

  • COST COMPARISON OF TREATING EARLY AND LATE COLORECTAL NEOPLASIA. Ahmad, S.; Phillips, E.; Vellacott, K. // Gut;Apr2003 Supplement 1, Vol. 52, pA94 

    The objective of this paper is to compare the cost of treating early colorectal neoplasia, to that of late neoplasia with on attempt to show that treating early colorectal neoplasia is more economical in comparison to late colorectal neoplasia. While we are debating the most effective method of...

  • Colorectal cancer risk greater among relatives of patients with serrated polyposis. Calabro, Anthony; Lawrence, Leah; Richards, Cassandra // Hem/Onc Today;7/10/2012, Vol. 13 Issue 13, p32 

    The article focuses on the results of a study analyzing generic clinics throughout the U.S., Canada and Australia, that revealed relatives of patients with serrated polyposis may be at greater risk for colorectal or pancreatic cancer.

  • City seeks to stamp out colon cancer.  // American City & County;Jan2004, Vol. 119 Issue 1, p16 

    Deals with the campaign against colon cancer staged by the residents of Monte Sereno, California in January 2004. Number of U.S. citizens the disease kills every year; Percentage of colon cancer cases occurring in people over age 50; Use of the Polyp Man mascot of American Cancer Society in the...

  • Neoprobe extends marketing, distribution deal with Ethicon.  // Medical Device Daily;12/21/2007, Vol. 11 Issue 232, p5 

    The article reports that Neoprobe extended its agreement with Ethicon Endo-Surgery pertaining to the marketing and distribution of neo2000 gamma detection systems for assisting in cancer diagnosis. The deal has been extended until 2013. Neoprobe president and chief executive officer (CEO) David...

  • Neoprobe gathers in $13M for pushing Lymphoseek R&D.  // Medical Technology & Devices Week;12/31/2007, Vol. 5 Issue 51, p4 

    This article focuses on the financing agreements signed by Neoprobe, a developer of oncology and cardiovascular surgical and diagnostic products, with Platinum Montaur Life Sciences. Under the securities purchase agreement, Neoprobe will receive $7 million which will be used to repay notes that...

  • Colon Cancer Quiz.  // Saturday Evening Post;Jul/Aug2005, Vol. 277 Issue 4, p50 

    Presents questions and answers about colorectal cancer.

  • The Future of Colorectal Screening Is in the Stool. Brand, R. E.; Thompson, Jon S. // American Journal of Gastroenterology;Mar2001, Vol. 96 Issue 3, p645 

    Discusses research being done on colorectal cancer screening by detection of altered human DNA in stool. Reference to a study by D. A. Ahlquist, J. S. Skoletsky and K. A. Boynton, published in a 2000 issue of the "Gastroenterology" journal; Detection of colorectal cancer using altered DNA assay...

  • Fiberoptic Sigmoidoscopy in Screening Pattern Makers for Colon Cancer at their Work Place. Ibrahim, Mostafa A. H.; Batra, Surinder K.; Schuman, Bernard M.; Viola III, Francis V. // American Journal of Gastroenterology;Apr1984, Vol. 79 Issue 4, p262 

    A large auto manufacturer screened its workers who belonged to the Pattern Makers (wood and metal workers) League of North America for colon cancer. Four-hundred nine asymptomatic workers were screened. Our group was only involved in performing most of the fiberoptic sigmoidoscopies in this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics